NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Combination therapies and multi-targeted drugs are crucial for overcoming cancer drug resistance.
• Signaling pathways like IGF1R/IRS1-2, STAT3, and AXL are vital in lung cancer development and progression.

Purpose of the Study:

• To investigate the preclinical efficacy and molecular mechanisms of the synthetic tyrphostin NT157 in lung cancer.
• To evaluate NT157's potential as a multi-targeted agent against lung cancer.

Main Methods:

• Assessing the effects of NT157 on lung cancer cell viability, clonogenicity, cell cycle, migration, and apoptosis.
• Analyzing changes in protein and gene expression, including key signaling molecules and oncogenes/tumor suppressor genes.
• Investigating NT157's interaction with EGFR inhibitors and identifying key kinases in its mechanism of action.

Main Results:

• NT157 significantly reduced lung cancer cell viability, clonogenicity, cell cycle progression, and migration while inducing apoptosis.
• NT157 decreased the expression of IRS1 and AXL and the phosphorylation of p38 MAPK, AKT, and 4EBP1.
• NT157 modulated oncogenes (BCL2, CCND1, MYB, MYC) and apoptosis-related genes (JUN, BBC3, CDKN1A, CDKN1B, FOS, EGR1), establishing a tumor-suppressive signaling network. JNK was identified as a key kinase for NT157-induced IRS1/IRS2 phosphorylation.
• NT157 demonstrated potentiating effects when combined with EGFR inhibitors in lung cancer cells.

Conclusions:

• NT157 exhibits significant antineoplastic activity in lung cancer through multi-targeted inhibition of critical signaling pathways.
• NT157 represents a promising prototype for a multi-targeted drug, potentially enhancing the therapeutic arsenal against lung cancer.
• The identification of JNK as a key kinase and the synergistic effects with EGFR inhibitors provide novel insights into NT157's mechanism of action.